Data from the MENAC trial were presented at 2024 ASCO Annual meeting (LBA12007) by lead researcher Tora S. Solheim, MD, PhD of the Cancer Clinic at St. Olavs Hospital, Norway. The MENAC trial addressed the complex issue of cachexia and if a multimodal treatment that combined exercise, proper nutrition, and anti-inflammatory medication may stall further weight loss in patients with cancer cachexia. The research involved international collaboration, recruiting patients from Norway, the UK, Canada, the US, and Switzerland. Initial findings show the intervention group maintaining weight more effectively than the control group, offering promising insights for clinical applications.
The study highlights the potential for integrative approaches to significantly improve patient care. The ASCO presentation drew considerable attention, underscoring the global interest in advancing supportive cancer therapies. Moreover, Dr Solheim is optimistic that these findings could pave the way for new standards in cancer treatment protocols, emphasizing the importance of holistic patient care. Future research aims to explore long-term benefits and the potential for wider application of the intervention across various cancer types.
For more information, visit HealthTalk.